Redcare Pharmacy NV

Redcare Pharmacy NV’s stock drops as Swiss OTC liberalisation looms; investors weigh the promise of market share gains against rising margin pressure.

Redcare Pharmacy NV’s March 4, 2026 report will reveal if German e‑prescription growth turns into profit, reshaping its €1.3 bn valuation and MDAX outlook.

Redcare Pharmacy’s new PoPP e‑Prescription integration boosts German market entry, slashes fulfillment time, and signals a 134% upside for investors.

Redcare Pharmacy NV’s mixed 4Q earnings show strong e‑prescription growth but falling profit, sparking investor caution yet analyst optimism for future online pharmacy expansion.

Redcare Pharmacy NV Aktie: trotz Umsatzwachstum 50 % Kursverlust seit Januar, CFO-Wechsel und Klärung einer Gesundheits‑Studie bringen kaum Erholung – Markt‑Verunsicherung im MDAX‑Sektor.

Redcare Pharmacy NV’s 25% revenue surge hit a new all‑time low – see why the stock fell and how investors can navigate the e‑pharmacy’s future.

Redcare Pharmacy NV has reported a 25% increase in Q3 revenue to €719 million, driven by growth in the e-prescription market in Germany, solidifying its position as Europe’s largest online pharmacy by revenue.

Redcare Pharmacy NV reported a 25.2% increase in revenue to €719 million in Q3 2025, driven by the expansion of electronic prescriptions in Germany and a 27% year-over-year rise in sales, surpassing analyst expectations.

Redcare Pharmacy NV’s stock price has surged over 5% after a German court ruling and technological advancements boosted investor confidence in the online pharmacy.

Redcare Pharmacy NV’s stock plummeted 20% after analyst downgrades and concerns over its e-prescription strategy, sparking market turbulence and uncertainty about the company’s future performance.